Výsledky vyhledávání - "Patrice Nasnas"

Akademický článek

How I Manage Chronic Lymphocytic Leukemia

Autor: Patrice Nasnas, Claudio Cerchione, Gerardo Musuraca, Giovanni Martinelli, Alessandra Ferrajoli

Publikováno v: Hematology Reports, Vol 15, Iss 3, Pp 454-464 (2023)

Chronic lymphocytic leukemia (CLL), is a hematologic malignancy characterized by the uncontrolled proliferation of mature B lymphocytes. CLL is the most prevalent leukemia in Western countries. Its presentation can range from asymptomatic with the in

Externí odkaz: https://doaj.org/article/1be75029557742e58f6ab194c326f8e1

Zobrazit plný text záznamu

Improved Outcomes with Low-Dose Inotuzumab and Mini-Hyper-CVD Followed By Blinatumomab Consolidation in Relapsed-Refractory Acute Lymphoblastic Leukemia: Results of a Phase II Study

Publikováno v: Blood. 140:11698-11701

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::9f900a65bdea93bd7569c54435a3c033
https://doi.org/10.1182/blood-2022-170049

Zobrazit plný text záznamu

Frontline Combination of Hyper-CVAD with Ponatinib for Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia-6-Year Follow-up Results

Publikováno v: Blood. 140:3250-3252

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::edf97354e6cf8c2ea3e6766bd59c201a
https://doi.org/10.1182/blood-2022-167761

Zobrazit plný text záznamu

Baseline Liver Elastography Does Not Predict Risks of Hepato-Toxicity to Reduced Dose Inotuzumab Therapy Combined with Minihcvd in B-Cell Acute Lymphoblastic Leukemia

Autor: Jayastu Senapati, Nicholas Short, Nitin Jain, Farhad Ravandi, Tharakeswara K. Bathala, Aram Bidikian, Fadi Haddad, Patrice Nasnas, Naval Daver, Tapan M. Kadia, Rebecca Garris, Monica Kwari, Hagop Kantarjian, Elias Jabbour

Publikováno v: Blood. 140:3182-3184

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::46fd63de2f4c58eec4ba578664d8cfda
https://doi.org/10.1182/blood-2022-170931

Zobrazit plný text záznamu

Roleof Allogeneic Stem Cell Transplant (ASCT) in Patients (Pts) with Relapsed/Refractory (R-R) Acute Lymphoblastic Leukemia (ALL) Treated with Inotuzumab Ozogamicin (INO) in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) with or without Blinatumomab (Blina): Results from a Phase 2 Study

Publikováno v: Blood. 136:39-41

Background: The combination of low intensity therapy with mini-hyper-CVD and INO with or without Blina has led to significant improvement in survival and outcomes of pts with R-R ALL. ASCT following salvage therapy is considered standard of care in p

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::2a45cb4fa631dc30e3d77928426d2d45
https://doi.org/10.1182/blood-2020-143286

Zobrazit plný text záznamu

Impact of Cytogenetic Abnormalities (CA) on Outcome of Patients (Pts) with Relapsed/Refractory (R-R) Acute Lymphoblastic Leukemia (ALL) Treated with Inotuzumab Ozogamicin (INO) in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) with or without Blinatumomab: Results from a Phase 2 Study

Publikováno v: Blood. 136:45-47

Background: The combination of INO with hyper-mini-CVD with or without blinatumomab offers a safe and effective treatment modality for pts with R-R ALL. However, the outcomes of some pts remain poor and the predictors of survival are not well underst

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::4fca7c129fc5c0e902862bd2bb4acd47
https://doi.org/10.1182/blood-2020-143401

Zobrazit plný text záznamu

Impact of Molecular Response at Specific Timepoints in Patients with Newly Diagnosed Chronic Myeloid Leukemia Treated with Second Generation Tyrosine Kinase Inhibitors

Autor: Tapan M. Kadia, Guillermo Garcia-Manero, Musa Yilmaz, Ghayas C. Issa, Rita Khouri, Patrice Nasnas, Hagop M. Kantarjian, Sara Dellasala, Sherry Pierce, Courtney D. DiNardo, Jorge E. Cortes, William G. Wierda, Naveen Pemmaraju, Koji Sasaki, Jeffrey Skinner, Elias Jabbour

Publikováno v: Blood. 136:42-44

Background: Tyrosine kinase inhibitors (TKI) improve survival in patients with chronic myeloid leukemia in chronic phase (CML-CP), who meet molecular milestones at specific timepoints. The European LeukemiaNet (ELN) revised the recommendations of mol

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::39c85e435ae7ff62fe890abcce9d35eb
https://doi.org/10.1182/blood-2020-143023

Zobrazit plný text záznamu

Outcome of Patients with Chronic Myeloid Leukemia in Lymphoid Blast Crisis (CML-LBC) and Philadelphia Chromosome (Ph)-Positive Acute Lymphoblastic Leukemia (ALL) Treated with Hyper-CVAD and Dasatinib

Autor: Guillermo Garcia-Manero, Tapan M. Kadia, Koichi Takahashi, Guillermo Montalban Bravo, Naval Daver, Kiyomi Morita, Farhad Ravandi, Rita Khouri, Patrice Nasnas, Koji Sasaki, Hagop M. Kantarjian, Jorge E. Cortes, Elias Jabbour, Courtney D. DiNardo, Nicholas J. Short, Ghayas C. Issa, Nitin Jain, Marina Konopleva

Publikováno v: Blood. 136:46-48

Introduction: Dasatinib monotherapy has demonstrated clinical activity in CML-LBC, however with limited duration of response and median overall survival (OS) Methods: We reviewed 81 pts (CML-LBC, N=19 and newly diagnosed Ph-positive ALL, N=62) who we

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::fc47bc114159c7b6d1f4e6afcc2de78a
https://doi.org/10.1182/blood-2020-141230

Zobrazit plný text záznamu

Blinatumomab for the treatment of acute lymphoblastic leukemia: an update

Autor: Caitlin R. Rausch, Patrice Nasnas, Shilpa Paul, Elias Jabbour, Hagop M. Kantarjian

Publikováno v: Expert Opinion on Orphan Drugs. 7:41-46

Introduction: Blinatumomab is a first-in-class bispecific T-cell engager (BiTE) antibody that has demonstrated high response rates, including minimal or measurable residual disease (MRD) negativity...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::bce9b9eb57ef5e0fbc8a3808c51193d7
https://doi.org/10.1080/21678707.2019.1571408

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání